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Abstract:  
Objectives: Hyperhomocysteinemia in Alzheimer’s disease (AD) is widely reported and 
appears to worsen as the disease progresses. While active dietary intervention with vitamins 
B12 and folate decreases homocysteine blood levels, with promising clinical outcomes in 
Mild Cognitive Impairment (MCI), this so far has not been replicated in established AD 
populations.  The aim of the study is to explore the relationship between 
hyperhomocystenemia and relevant vitamins as the disease progresses. 
Methods:  In this longitudinal cohort study, 38 participants with mild to moderate AD were 
followed for an average period of 13 months. Plasma folate, vitamin B12 and homocysteine 
concentrations were measured at baseline and at follow-up. Dietary intake of B vitamins was 
also measured. Spearman’s correlations were conducted by homocysteine and B vitamin 
status. 
Results:  As expected, cognitive status significantly declined over the follow-up period and 
this was paralleled by a significant increase in homocysteine concentrations (p=0.006). 
However, during this follow-up period there was no significant decline in neither dietary 
intake, nor the corresponding blood concentrations of vitamin B12/folate, with both 
remaining within normal values. Changes in blood concentrations of B vitamins were not 
associated with changes in homocysteine levels (p>0.05). 
Conclusion:  In this study, the increase in homocysteine observed in AD patients as the 
disease progresses cannot be solely explained by dietary and blood levels of folate and 
vitamin B12. Other dietary and non-dietary factors may contribute to hyperhomocysteinemia 
and its toxic effect in AD, which needs to be explored to optimise timely intervention 
strategies.  
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1. Introduction 
Dementia is a common disorder with its prevalence set to rise worldwide. In the absence of a 
cure there is a growing need to identify treatments that can slow the cognitive progression of 
the disease, thus enabling those with dementia to retain appropriate functional abilities for 
longer. Currently, there are only a small number of symptomatic medications licensed for the 
treatment of Alzheimer’s disease (AD), the most prevalent type of dementia. Importantly, the 
effectiveness of these licensed medications are often considered limited (Casey et al., 2010). 
Abnormal elevation of homocysteine levels has been implicated as a marker for AD. 
Hyperhomocysteinemia is associated with increased cognitive decline in healthy older adults 
with higher risk of cognitive impairment (e.g. (Morris, 2012; Smith et al., 2010; Vogel et al., 
2009). Apart from a few notable exceptions, most studies report mild to moderate 
hyperhomocysteinemia in dementia populations compared to healthy controls (for a review 
see (Zhuo et al., 2011). However, research into the specific role of homocysteine on cognitive 
decline in a population with established AD is limited. Although not consistently reported 
(e.g. (Huang et al., 2010), studies have found that homocysteine levels in AD can predict 
rates of cognitive decline (Huang et al., 2013; Oulhaj et al., 2010). 
It has therefore been of interest to establish whether reducing homocysteine levels can have a 
beneficial effect on the slowing down of AD progression. A key avenue of research is the 
supplementation with vitamin B12 and folate. These vitamins act as cofactors for the 
methylation of homocysteine to methionine, and therefore in the absence of these dietary 
nutrients homocysteine concentrations increase. It has been estimated that 65% of the 
hyperhomocysteinemia cases among the Framingham elderly population-based cohort could 
be accounted for by inadequate folate, or, to a lesser extent, inadequate vitamin B12 or 
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vitamin B6 status and intake (Selhub et al., 1993). It has even been shown that B vitamins 
taken at the earliest stages of the disease (i.e. Mild Cognitive Impairment (MCI)) are able to 
slow down the rate of brain atrophy (Smith et al., 2010) as well as the cognitive decline (de 
Jager et al., 2012), and may reduce conversion rates into dementia (Blasko et al., 2013). 
Despite this, there is little evidence that increasing the intake of these vitamins are able to 
combat cognitive decline later in the disease course, i.e. among participants with established 
AD. Serum levels of vitamin B12 have been found to have no association with cognitive 
progression in AD populations (Huang et al., 2010; Oulhaj et al., 2010; Small et al., 1997a, 
1997b; Tu et al., 2010). Randomised controlled trials (RCTs) in AD populations have found 
that relevant vitamin treatments are unable to attenuate cognitive progression in the samples 
as a whole (Aisen et al., 2008; Kwok et al., 2011; Sun et al., 2007). Interrogation of these 
findings suggest that B vitamin supplementation may still have a role in attenuating cognitive 
decline in AD only in the presence of particularly elevated homocysteine levels. For example, 
Kwok and colleagues found that participants who received B vitamin treatment with elevated 
levels of homocysteine (13 μmol/L or greater) had significantly smaller decline in the 
construction domain of Mattis Dementia Rating Scale (MDRS) than those receiving placebo 
(Kwok et al., 2011). Interestingly, participants in another study that had more modest levels 
of homocysteine (mean = 9.2 μmol/L, SD = 3.2) at the onset of the trial did not report any 
positive effects on cognition, while a subgroup with mild AD showed some benefit of the 
treatment (Aisen et al., 2008).  
Discerning the exact role of homocysteine and B vitamins on cognitive decline is 
complicated, as hyperhomocysteinemia is only one of many contributing markers in the 
disease progression. The neurotoxicity of homocysteine and its direct effect on brain atrophy 
has been established (Madsen et al., 2015). Unlike the early indications from MCI, lowering 
homocysteine levels in established AD may not produce the same clinical benefits as research 
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so far has shown. Other non-dietary factors may also contribute to hyperhomocysteinemia 
and moderate its toxicity. Longitudinal studies assessing the relationship between 
homocysteine concentrations and cognitive decline in established AD, and its possible 
association with both dietary and blood vitamin B12 and folate levels, are limited (Clarke et 
al., 1998; Oulhaj et al., 2010).  
The aim of this study was to establish whether the extensively reported 
hyperhomocysteinemia in AD as the disease progresses is associated with dietary and blood 
levels of B vitamins. In line with current knowledge, we hypothesised that blood 
homocysteine levels would significantly increase over the follow-up period. In addition, we 
hypothesised that this increase in homocysteine is explained by an associated decrease in 
vitamin B levels.  
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2. Materials and Methods 
2.1 Participants 
All participants were recruited in Sussex (UK) memory assessment clinics and had mild to 
moderate AD (MMSE>12). The mean age of AD participants was 81.3 years (SD=6.0). The 
inclusion and exclusion criteria for this study has previously been reported elsewhere (Farina 
et al., 2016).  In brief, eligible participants had previously been clinically assessed using the 
International Statistical Classification of Diseases, 10th revision (ICD-10; World Health 
Organisation, 1992), and received a diagnosis of probable dementia of Alzheimer’s type.  AD 
patients all had a personal consultee (relative or friend), and were either clinically or self-
referred. For inclusion in the study described here, participants were also required to provide 
a blood sample on two occasions so that homocysteine concentrations could be measured. 
Ethical approval was obtained from a National Research Ethics Service Committee. 
 
2.2 Neuropsychological testing and dietary data 
Demographic data including age, gender and ethnicity were recorded. As previously reported 
(see Farina, Tabet, & Rusted, 2016), a battery of neuropsychological tests and the Food 
Frequency Questionnaire (FFQ) were completed by participants and lasted approximately 2-3 
hours. The Addenbrooke’s Cognitive Examination Revised (ACE-R; Mioshi et al., 2006) was 
used to provide a standardised measure of dementia severity. The ACE-R total score was also 
used as a comprehensive measure of global cognitive status. The Cornell Scale of Depression 
in Dementia (CSDD; Alexopoulos et al., 1988) was used to screen for the potential presence 
of major depression. IQ was estimated using the National Adult Reading Test (NART; 
Nelson, 1982).  
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Dietary intake of nutrients were estimated using the EPIC FFQ (Bingham et al., 2007). The 
questionnaire was completed by the carer of the participant, who described the average 
dietary intake of the participant over the past year. Once collected, data was analysed by the 
Department of Nutritional Sciences, University of Surrey, UK. Nutritional values for 
individual foods were estimated and summed. Nutrient intakes were expressed as percentages 
of the age and gender appropriate Recommended Nutritional Intakes (RNIs).  
 
2.3 Biochemical assays 
Plasma homocysteine, vitamin B12, and folate were analysed at the Department of 
Pharmacology, University of Oxford. Plasma concentrations of total Cobalamin (B12) and 
folate were measured by automated (Perkin-Elmer MultiProbe 11 liquid handling system, 
Perkin-Elmer Life and Analytical Sciences) microbiological assays using Lactobacillus 
leichmanii and L. casei, respectively (Kelleher and Broin, 1991; Molloy and Scott, 1997). 
Between-day coefficients of variation for B12 were 7.1%, and 7.4% for folate. Total plasma 
homocysteine was analysed by liquid-chromatography according to a modified protocol 
described previously (Refsum et al., 2004), using a QTRAP 5500 (AB Sciex, Framingham, 
Massachusetts, US) coupled to a Prominence LC-20ADXR binary pump (Shimadzu, Kyoto, 
Japan). In short, 10 µL of plasma was added to an equal volume of an internal standard mix 
containing isotopically labelled homocysteine. Samples were neutralised using an ammonia 
solution before reduction with dithioerythriol at room temperature for 15 min. Plasma 
proteins were precipitated with perchloric acid (4% v/v) and cleared by centrifugation. 
Supernatant was diluted 1:10 in water/sodium 1-heptane sulfonate [1M]/ perchloric acid 
[20%, 3.3 M] 5/3/1 v/v/v, and injected onto a Kinetex C18 column (30 x 4.6 mm, 2.6 μm, 
Phenomenex, Torrance, CA, US) at a flow rate of 0.8 mL/min. Gradient elution was 
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employed starting at 100% mobile phase A (water + 0.05% formic acid), with a final 
composition of 40% A and 60% mobile phase B (methanol + 0.05% formic acid). Data 
acquisition and analysis were performed with Analyst 1.6.1 (AB Sciex, Framingham, 
Massachusetts, US). Quantitation was based on the ratio of analyte peak area/internal 
standard peak area against a linear calibration curve with a 1/x weighting. The coefficient of 
variation for was 4.0%. 
 
2.4 Statistical Analysis 
Descriptive statistics (e.g. means and frequencies) were reported for the participant 
demographics. All findings reported were of participants that were able to provide a sample 
of blood at baseline and at follow-up so that plasma homocysteine concentrations could be 
analysed. A series of Spearman’s Rho correlations were conducted between baseline 
measures of B vitamin status and plasma homocysteine levels to determine the relationship 
between them. Additional Spearman’s Rho correlations were run between B vitamin status 
and homocysteine change scores. No adjustments were made for multiple comparisons. 
Vitamin B12 and folate levels, plasma homocysteine and global cognitive status were 
compared between time points. Plasma homocysteine scores were logarithmically 
transformed. For non-parametric data, a Wilcoxon Signed Rank test was used, and for 
parametric data, a Paired-sample t-test was used.  
The statistical significance threshold was set at p< 0.05. All statistical analyses were 
performed using SPSS (IBM SPSS statistics V.21; SPSS Inc, Chicago, Illinois, USA). 
 
3. Results 
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3.1. Demographics 
Thirty-eight participants with a diagnosis of AD met the inclusion criteria and were tested at 
baseline and on average 389.4 days later (SD= 26.2). Participants mean age was 81.3 years 
(SD=6.0), had a mild to moderate diagnosis at baseline, and were all free from major 
depression (CSDD ≤ 10). See Table 1 for full participant demographics. 
-----Table 1 Here ----- 
 
3.2. Validation of dietary intake vs plasma levels of B vitamins 
Dietary intake of vitamin B12 did not significantly correlate with plasma vitamin B12 
concentrations at baseline (rs = .12, p= .46) or at follow-up (rs = -.18, p = .29). Dietary intake 
of folate did however significantly correlate with plasma folate at baseline (rs = .43, p< .01) 
but not at follow-up (rs = .06, p = .72). 
 
3.2. The relationship between plasma homocysteine concentrations and vitamin B12 and 
folate status 
Baseline plasma homocysteine concentrations significantly correlated with plasma folate (rs = 
-.58, p < .001) and vitamin B12 concentrations (rs = -.42, p < .01). Baseline plasma 
homocysteine concentrations also significantly correlated with dietary intake of folate (rs = - 
.34, p= .04), but not with dietary intake of vitamin B12 (rs = -.20, p= .24). See Table 2. 
-----Table 2 Here ----- 
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3.3. Longitudinal changes in dietary intake and plasma levels 
Dietary and plasma levels of vitamin B12 and folate declined between time-points.  However, 
we only observed borderline significant decrease in plasma B12 concentrations (p= .05). 
Interestingly, plasma homocysteine concentrations significantly increased between time-
points (p= .001) as presented in Table 3.   
-----Table 3 Here ----- 
 
3.4. Relationship between B vitamins and change in homocysteine 
No baseline indices of vitamin B status was significantly associated with longitudinal 
changes of plasma homocysteine (p>0.05) (See Table 2). However, there was a trend toward 
significance between change in homocysteine compared to change in plasma B12 levels (rs = 
-.30, p = .07). This was not observed when compared to changes in plasma folate levels (rs = -
.10, p= .54). 
 
4. Discussion 
The primary aim of this research was to assess whether the longitudinal changes in 
homocysteine levels were related to B vitamin (vitamin B12 and folate) concentrations in a 
cohort with established AD. This study found that homocysteine levels did increase over the 
study period, even in a cohort with high homocysteine levels at baseline. However, we were 
unable to show that the continued increase in homocysteine levels were driven by changes in 
B vitamin status. 
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It is important to highlight that participants in this study reported consuming well above the 
Reference Nutritional Intake (RNI; (Department of Health, 1991) for folate (mean = 169.6 %) 
and vitamin B12 (mean = 529.3%) at baseline. Whilst FFQs do tend to overestimate intake, 
there is an indication in the present sample that patients during the early stages of AD consume 
nutrients sufficient to meet the requirements of 97.5% of their non-dementia counterparts. In 
addition, the corresponding plasma concentrations of folate and vitamin B12 were deemed as 
being well above deficiency levels (Smith and Refsum, 2012; World Health Organization, 
2012). There was also no significant decline in B vitamin intake and plasma concentrations 
over the study period. In any case, all values were still safely well above recommended levels 
at the end of the study. In contrast, plasma homocysteine concentrations significantly increased 
between time-points. Therefore, it can be inferred that maintaining an adequate day-to-day 
intake of B vitamins, even in the relatively high homocysteine levels reported in this sample, 
is insufficient to maintain baseline homocysteine levels. Correlation analysis between change 
in homocysteine scores and indices of B vitamin status revealed that there was no significant 
association, though a trend was found between change in B12 levels and homocysteine levels 
(p=0.07). This raises the question whether other factors may be contributing to increasing 
homocysteine levels within AD and indirectly may explain that why clinical trials with 
established AD has not so far shown clinical benefit. It has previously been recommended that 
higher B vitamin target concentrations are needed to control homocysteine concentrations in 
certain populations  (Smith and Refsum, 2012) and whilst the present study does not provide 
direct evidence to support this recommendation, it certainly could explain some of our current 
findings.  
More favourable data has been presented in a MCI cohort where vitamin supplementation not 
only lowered homocysteine levels but protected against brain atrophy (Smith et al., 2010),   and 
cognitive and clinical decline in those with elevated homocysteine at baseline (de Jager et al., 
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2012). It is still worth acknowledging that the role of homocysteine in the progression of AD 
is likely to be more complex, and may interact with other factors. For example, B vitamin 
supplementation only slowed brain atrophy rates and cognitive decline in participants with 
sufficiently high plasma levels of omega-3 fatty acids in a MCI population (Jernerén et al., 
2015; Oulhaj et al., 2016).  Omega-3 fatty acids were not measured in the present study, and 
therefore we are unable to comment on the role of omega-3 in the context of the current 
findings. 
 
This study has several limitations which need to be acknowledged. A key limitation is that the 
relatively small sample size increases the likelihood of type II error. Dietary intake estimates 
calculated from the FFQ should not be considered as absolute values but rather estimates for 
the comparison within and between participants at different time-points. The participants 
recruited for this study were recruited for the purposes to identify the role of lifestyle factors 
on the cognitive progression of dementia (see Farina et al., 2016), and as a result no control 
group was recruited. This prevents us from discussing how these vitamins and homocysteine 
concentrations in our sample differ to a cognitively healthy population, and whether the 
increase in homocysteine over time reported here differs significantly from what we expect in 
age-matched controls (Frick et al., 2004; Refsum et al., 2004). However, it is well established 
that homocysteine levels are elevated in AD compared to healthy controls (for review see 
(Zhuo et al., 2011). The mean homocysteine concentration at baseline reported in the present 
study, 16.0 μmol/L, is considered elevated and is not dissimilar to that reported in a similar AD 
cohort  (e.g. mean age = 82.8 years, average total homocysteine = 18.3 μmol/L) (Joosten et al., 
1997).  Another potential limitation is the choice of measurement for B vitamin status in the 
bloods, which may have affected accuracy.  For example, holotranscobalamin (holoTC) has 
been argued as being more reliable marker of B12 status than total vitamin B12 alone 
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(Harrington, 2017), particularly in those who are vitamin B12 deficient (Nexo and Hoffmann-
Lücke, 2011).  
In summary, AD patients in the present sample showed stable and adequate levels of folate and 
vitamin B12 for the duration of the study, based on commonly used recommendations and cut-
off values.  Despite this, homocysteine levels were elevated at baseline and increased further 
as the disease progressed.  Whilst there is an established relationship between elevated 
homocysteine and dietary intake of B vitamins in older adults (Selhub et al., 1993), this study 
could indicate that the recommended guidelines in terms of plasma levels of B vitamins might 
have to be reconsidered, as suggested by others (Smith and Refsum, 2012). However, we 
should not neglect the potential of other factors, with evidence from a MCI population 
identifying omega-3 may contribute to hyperhomocysteinemia (Jernerén et al., 2015; Oulhaj et 
al., 2016). Overall this might explain why so far dietary vitamin B intervention has not showed 
direct clinical benefit in AD. Ultimately, understanding the underlying mechanism of 
hyperhomocystemia in AD beyond vitamin B cofactors might help better optimise treatment 
strategies, which may result in direct clinical benefit to patients.  
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Table 1. Baseline demographic data of AD participants (n=38) 
 % Mean SD 
Age (years)  81.3 6.0 
Gender 
 Male 
 Female 
 
53 
47 
  
Diagnosis 
 AD 
 Mixed 
 
71 
29 
  
Race 
 Caucasian 
 
100 
  
Time Since Diagnosis 
(years) 
 1.1 1.5 
Premorbid IQ   115.0 8.9 
Age leaving full-time 
education (years) 
 16.1 2.4 
Pulse Pressure (Systolic 
Pressure – Diastolic 
Pressure) 
 75.4 16.8 
Creatinine (μmol/l)  91.9 31.5 
Cornel Scale of 
Depression in Dementia 
 2.5 2.7 
Body Mass Index   26.2 3.8 
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Table 2. Spearman’s correlation between ACE-R change scores, baseline dietary B vitamins, baseline plasma B vitamins and baseline plasma 
homocysteine concentrations.  
 Baseline Dietary Vitamin 
B12 
Baseline Plasma 
Folate 
Baseline Plasma 
Vitamin B12 
Baseline Plasma 
Homocysteine  
Plasma Homocysteine 
Change scores 
 rs p rs p rs p rs p rs p 
Baseline Dietary 
Folate 
.44 .006 .43 .008 -.11 .531 -.34 .039 .01 .972 
Baseline Dietary 
Vitamin B12 
  .27 .100 .12 .457 -.20 .236 .11 .508 
Baseline Plasma 
Folate 
    .26 .116 -.58 < .001 -.21 .201 
Baseline Plasma 
Vitamin B12 
      -.42  .009 0.08 .643 
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Table 3. The means (and standard deviations) of blood and dietary markers of B vitamins, plasma homocysteine and global 
cognition at each time-point for participants that completed both time points (n=38).   
 Baseline Follow-up   
 Mean SD Mean SD Diff (95% CI) p 
Plasma       
 Homocysteine (μmol/l) 16.0 5.3 17.4 6.3 1.3 (0.6, 2.1) .001 
 B12 (pmol/l) 347.0 171.0 311.4  207.9 -35.6 (-91.3, 20.1) .053 
 Folate (nmol/l) 25.9  23.3 21.8 19.5 -4.2 (-10.9, 2.6) .175 
Diet       
 B12 (%, RNI) 529.3 286.3 498.6 206.6 -30.7 (-124.1, 62.6) 1.00 
 Folate (%, RNI) 169.6  58.3 168.8 101.1 -0.7 (-25.3, 23.8) .085 
Global Cognition       
 ACE-R 69.6 10.0 65.6 13.3 -4.0 (-6.8, -1.2) .006 
RNI: Recommended Nutritional Intake, ACE-R:  Addenbrooks Cognitive Examination-Revised, CI: Confidence Intervals 
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